Bayer warns US lawmakers it may halt Roundup sales without stronger legal protections: report
Bayer AG (ETR:BAYN, OTC:BAYZF) has told US lawmakers it may halt sales of its popular Roundup weedkiller in the United States unless stronger legal protections are implemented to protect the company from ongoing product liability lawsuits, according to a Reuters report citing a source with knowledge of the matter. The German company has already paid about $10 billion to settle claims alleging that the herbicide glyphosate featured in Roundup causes cancer.
Bayer seeks investor approval for 35% cash call to gird for litigation
Bayer said on Friday it would seek shareholder approval to raise fresh equity capital worth close to 35% of its currently outstanding shares over the next three years to be ready for any U.S. litigation settlement.
Bayer eyes exit from popular Roundup amid US legal risks
Bayer has warned U.S. lawmakers it could stop selling the popular Roundup weedkiller if they cannot provide better legal protection against product liability litigation, according to a financial analyst and a person familiar with the matter.
Bayer Q4 Earnings In Line, Revenues Top on Nubeqa, Kerendia Sales
BAYRY's fourth-quarter earnings match expectations. Revenues top estimates, driven by the strong performance of its pharmaceutical business.
Bayer CEO: 2025 Will Be 'Most Difficult' Year In Turnaround Plan, Expects Improved Performance From 2026 Onwards
On Wednesday, Bayer AG BAYRY reported fourth-quarter 2024 adjusted EPS of $0.28, missing the consensus of $1.00.
Bayer sees improvement in 2026 after profit decline this year
Bayer on Wednesday raised the prospect of a return to earnings growth next year after reiterating that a decline was expected for this year.
Bayer faces investors' impatience ahead of fourth-quarter results
Bayer's CEO is facing increasing investor pressure to deliver on turnaround efforts and reverse a forecast earnings decline this year, as the group prepares to release quarterly results on Wednesday.
Bayer: A Contrarian Thesis
Bayer's diversified portfolio and robust late-stage pharmaceutical pipeline are expected to stabilize revenues despite LoE concerns, particularly with Xarelto facing generic competition. The Crop Sciences division, despite ongoing glyphosate litigation, holds significant upside potential due to its expansive R&D pipeline and market undervaluation. High leverage ratio constrains capital allocation optionality.
IQ-AI's Imaging Biometrics expands distribution deal with Bayer's Blackford
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) subsidiary Imaging Biometrics has expanded its distribution agreement with artificial intelligence imaging platform provider Blackford Analysis, which is an arm of German giant Bayer AG. Imagine Biometrics's IB Nimble, IB ASL, IB FTB and IB FTB Express have all been added to the existing distribution agreement, allowing Blackford to also sell these products to its global client base of healthcare providers.
Bayer must pay $100 million in latest trial over PCBs in Washington school, jury finds
A Washington state jury on Tuesday said Bayer must pay $100 million to four people who say they were sickened by exposure to toxic chemicals known as PCBs made by the company's predecessor Monsanto that were used in light fixtures at a Seattle-area school, but found that the company was not liable for injuries alleged by ten others, according to a lawyer for the plaintiffs.
Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview published on Tuesday.
Bayer's Stock Hits 2-Decade Low: Why It Is A Buy Again
Bayer's stock has declined below €20, with Q3/24 results showing a 3.6% sales decrease and a 29.8% EBITDA drop, mainly due to currency effects. Crop Science sales fell 9.1% YoY, and Pharmaceuticals saw mixed results with Nubeqa and Kerendia growing, but Xarelto declining 23.8% due to generics. Bayer's strategic transformation under CEO Bill Anderson aims to decentralize decision-making, but litigation issues and high debt levels remain significant challenges.
